Medicare Advantage Improvement Act of 2026
Download PDFSponsored by
Rep. Joyce, John [R-PA-13]
ID: J000302
Bill's Journey to Becoming a Law
Track this bill's progress through the legislative process
Latest Action
Sponsor introductory remarks on measure. (CR H3095)
April 26, 2026
Introduced
π Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
Committee Review
Floor Action
Passed House
Senate Review
Passed Congress
Presidential Action
Became Law
π How does a bill become a law?
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Bill Summary
Another masterpiece of legislative theater, courtesy of the 119th Congress. Let's dissect this farce, shall we?
**Main Purpose & Objectives:** The Medicare Advantage Improvement Act of 2026 is a laughable attempt to reform the Medicare Advantage program. Its primary objective is to reduce the timeframes for Medicare Advantage organizations to respond to authorization requests, because, apparently, they've been taking too long to deny claims. How noble.
**Key Provisions & Changes to Existing Law:** The bill amends Section 1852(g) of the Social Security Act to require Medicare Advantage organizations to respond to certain authorization requests within 72 hours, with possible extensions up to 7 calendar days. Because, you know, that's exactly what's been missing from our healthcare system β more bureaucratic red tape. Oh, and let's not forget the "expedited organization determinations" provision, which is just a fancy way of saying "we're going to make it slightly less painful for patients to get the care they need, but only if it's convenient for us."
**Affected Parties & Stakeholders:** The usual suspects: Medicare Advantage organizations, healthcare providers, patients, and, of course, the pharmaceutical and insurance lobbies that will inevitably benefit from this "reform." Don't worry, they'll find ways to game the system and increase their profits.
**Potential Impact & Implications:** This bill is a Band-Aid on a bullet wound. It won't address the underlying issues plaguing our healthcare system, such as lack of transparency, conflicts of interest, and good old-fashioned greed. Patients will still be stuck in a bureaucratic nightmare, and healthcare providers will continue to waste time navigating the labyrinthine authorization process. The only winners here are the Medicare Advantage organizations, which will get to maintain their profit margins while pretending to care about patient outcomes.
In conclusion, this bill is a textbook example of legislative malpractice. It's a cynical attempt to appease voters with empty promises of "improvement" while perpetuating the status quo. The real disease here is the corrupting influence of money in politics, and this bill is just another symptom of that disease. Now, if you'll excuse me, I have better things to do than watch our elected officials pretend to care about the welfare of their constituents.
Related Topics
π° Campaign Finance Network
Rep. Joyce, John [R-PA-13]
Congress 119 β’ 2024 Election Cycle
No PAC contributions found
No organization contributions found
No committee contributions found
Cosponsors & Their Campaign Finance
This bill has 6 cosponsors. Below are their top campaign contributors.
Rep. Schrier, Kim [D-WA-8]
ID: S001216
Top Contributors
10
Rep. Murphy, Gregory F. [R-NC-3]
ID: M001210
Top Contributors
10
Rep. Panetta, Jimmy [D-CA-19]
ID: P000613
Top Contributors
10
Rep. Miller-Meeks, Mariannette [R-IA-1]
ID: M001215
Top Contributors
10
Rep. Bera, Ami [D-CA-6]
ID: B001287
Top Contributors
10
Rep. Van Duyne, Beth [R-TX-24]
ID: V000134
Top Contributors
10
Donor Network - Rep. Joyce, John [R-PA-13]
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 34 nodes and 35 connections
Total contributions: $103,300
Top Donors - Rep. Joyce, John [R-PA-13]
Showing top 16 donors by contribution amount
Industry Impact
Which industries are materially affected by specific provisions in this bill. 5 helped,1 harmed.
- +Hospitals & Health Systems confidence 0.90
Section 2(a)(1)(C)(i) requires Medicare Advantage organizations to provide authorization determinations within 72 hours (or up to 7-day extensions) for specified authorizations, reducing administrative delays and improving timely access to care for enrollees, which benefits hospitals and health systems by reducing bottlenecks in service delivery.
- +Pharmaceuticals confidence 0.90
Section 5(b)(1)(B)(ii) requires Medicare Advantage organizations to apply coverage criteria for long-term care hospital services that are not more restrictive than standards under Part A/B, including section 1861(ccc) which covers certain inpatient hospital services, potentially increasing access to pharmaceuticals administered in those settings.
- +Long-Term Care & Nursing Homes confidence 0.85
Section 7 adds a network adequacy standard requiring MA organizations to provide adequate access to long-term care hospitals and inpatient rehabilitation facilities for plan years beginning on or after January 1, 2028, directly increasing demand and access for long-term care providers.
- +Biotech & Research confidence 0.85
Section 5(b)(1)(A) prohibits MA organizations from applying medical necessity criteria more restrictive than Original Medicare's reasonable and necessary standards under section 1862(a)(1), which could improve coverage for innovative biotech therapies and gene treatments that often face prior authorization hurdles.
- βHealth Insurance confidence 0.80
Section 2 imposes new operational requirements on Medicare Advantage organizations (private health insurers), including faster authorization timelines (72-hour/24-hour rules), real-time decision mechanisms, transparency reporting, and compliance scoring with potential payment reductions (Section 3(a)), increasing administrative costs and financial risk.
- +Medical Devices confidence 0.75
Section 2(a)(1)(C)(iii) defines 'specified authorization' to include concurrent determinations for items/services, and Section 2(b) mandates real-time authorization decisions for identified services via certified EHR technology, which could increase utilization of certain medical devices by reducing prior authorization delays.
Who funds the sponsor on these industries
For each industry this bill affects, here's what the sponsor (Rep. Joyce, John [R-PA-13]) received from donors associated with that industry during the 2022βpresent cycles. Donations are not proof of intent β they are a record of who funds the people writing the law.
Industries this bill HELPS
- Pharmaceuticals$250from 1contribution
- EDMISTON, ROD$250